Argenx Se (ARGX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenx SE has presented promising data at the 2024 Peripheral Nerve Society Annual Meeting, highlighting significant advancements in its autoimmune pipeline. New study results show that empasiprubart, the company’s novel therapy for Multifocal Motor Neuropathy (MMN), could substantially reduce the risk of relapse and improve functional abilities for patients. Additionally, the FDA-approved VYVGART Hytrulo has demonstrated consistent, sustained efficacy and safety in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), offering improved and maintained functional benefits for patients.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.